Residual Renal function (RRF) has an important role in the overall morbidity and mortality in hemodialysis patients. The role of angiotensin-converting enzyme inhibitor (ACEi) in preserving renal function in chronic proteinuric nephropathies is well documented. We test the hypothesis that enalapril (an ACEi) slows the rate of decline of RRF in patients starting hemodialysis. A prospective, randomized open-label study was carried out. 42 patients were randomized in two groups either in treatment with enalapril or no treatment at all. Our study has proven that enalapril has a significant effect on preserving residual renal function in patients starting dialysis at least during the first 12 months from the initiation of the hemodialysis. Further studies are necessary in order to investigate the potential long-term effect of ACEi on residual renal function and on morbidity and mortality in patients starting hemodialysis.
10 September 2010 in Journal of Medical Case Reports
The kidney is increasingly recognised as a target organ of chronic graft-versus-host disease after hematopoietic cell transplantation in the context of the development of the nephrotic syndrome. Chronic graft-versus-host disease is associated with autoimmune phenomena similar, but not identical, to those observed in various rheumatologic disorders, implicating autoimmunity as an important component of the disease.
Background. IgA glomerulonephritis may present with hematuria, flank pain, and fever. This clinical presentation may be easily confused with acute pyelonephritis.Case Report. We present the case of a 25-year-old female with a typical clinical presentation for acute pyelonephritis (high fever, left flank pain, left costovertebral angle tenderness, hematuria, elevated inflammatory markers, and a hypoenhancing region in the left kidney on contrast-enhanced computed tomography). However, urine and blood cultures were both negative, the serum creatinine was elevated, and the urinalysis revealed significant proteinuria and dysmorphic red blood cells. A kidney biopsy confirmed a diagnosis of IgA nephropathy. She was treated with a combination of lisinopril and methylprednisolone, with good response.Conclusion. Gross hematuria, especially in the absence of pyuria or bacteriuria, should raise the suspicion for underlying IgA nephropathy, even if the rest of the clinical presentation is typical for a urinary tract infection. The presence of significant proteinuria, red blood cell casts, and dysmorphic red blood cells are useful clues suggesting glomerular disease.
INTRODUCTION AND AIMS: According to recent studies, a central role to the pathogenesis of IgA nephropathy (IgAN) is the formation of circulating immune complexes between IgA and CD89 (a soluble receptor). Due to the frequency of end stage renal disease attributed to IgA nephropathy and the relative scarce predictive tools of its progression, with the present study, we aimed to investigate whether circulating CD89-IgA levels can predict the renal outcome in patients with IgAN.
Disturbances of carbohydrate metabolism are common in patients with chronic kidney disease (CKD). Possible pathogenetic mechanisms involve unresponsiveness of insulin receptor and/or a bland response of the beta cell at the stimulus of hyperglycaemia. It is known that vitamin D has an important role in the endocrine function of the pancreas, particularly in the insulin release process, and is one of the determinants of insulin resistance [1]. This metabolic complication may be implicated in the accelerated atherosclerotic process and is common in CKD. The aim of our study was to investigate the effect of vitamin D treatment on insulin resistance in patients with CKD stage 3.